Summary
TE Connectivity Ltd. (TEL) announced on February 1, 2016, that it has entered into a definitive agreement to acquire the Creganna Medical group for an aggregate cash purchase price of $895 million. This strategic acquisition will be made through the purchase of 100% of the equity and certain loan notes of Creganna Medical. The acquisition is subject to customary closing conditions, including regulatory approvals from antitrust authorities in the U.S., Austria, Costa Rica, and Ireland. The transaction is expected to strengthen TE Connectivity's position in the medical device industry, aligning with the company's strategy to expand its presence in high-growth markets.
Key Highlights
- 1TE Connectivity Ltd. agreed to acquire Creganna Medical group for $895 million in cash.
- 2The acquisition involves purchasing 100% of Creganna Medical's equity and loan notes.
- 3The transaction is subject to customary closing conditions, including various antitrust approvals.
- 4Regulatory clearance is required from the U.S. (Hart-Scott-Rodino), Austria, Costa Rica, and Ireland.
- 5The acquisition is expected to enhance TE Connectivity's capabilities and market presence in the medical technology sector.
- 6The filing notes the inclusion of forward-looking statements and associated risks, typical for M&A announcements.
Frequently Asked Questions
TE Connectivity is acquiring the Creganna Medical group for an aggregate cash purchase price of $895 million. This includes 100% of the equity and certain loan notes of Creganna Medical.
The transaction is subject to customary closing conditions, which include the expiration or termination of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act, clearance from antitrust authorities in Austria, Costa Rica, and Ireland, and the absence of any governmental injunctions or orders restraining the transaction.
While not explicitly detailed in this 8-K, the acquisition of Creganna Medical, a medical device component provider, is expected to strengthen TE Connectivity's position and capabilities within the growing medical technology market, aligning with the company's strategic focus on high-growth sectors.
The 8-K filing does not provide a specific expected closing date. The consummation of the transaction is contingent upon satisfying the aforementioned closing conditions, including regulatory approvals.